MedTech — Research and development expense
Business Segments · Research and development expenseJohnson & Johnson MedTech — Research and development expense increased by 12.5% to $728.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 1.5%, from $739.00M to $728.00M. Over 2 years (FY 2022 to FY 2024), MedTech — Research and development expense shows an upward trend with a 21.9% CAGR.
Analysis
StatementSegment
CategoryGrowth
SignalContext dependent
VolatilityModerate
First reportedQ1 2022
Last reportedQ3 2025
How to read this metric
Higher investment generally signals a commitment to long-term innovation and future growth potential.
Detailed definition
Captures the investment in innovation, clinical trials, and product development within the MedTech segment. This reflect...
Peer comparison
Standard R&D reporting for life sciences and technology companies.
Metric ID:
jnj_segment_medtech_research_and_development_expenseHistorical Data
15 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $623.25M | $623.25M | $623.25M | $623.25M | $780.50M | $780.50M | $780.50M | $780.50M | $646.00M | $718.00M | $739.00M | $1.60B | $677.00M | $647.00M | $728.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +25.2% | +0.0% | +0.0% | +0.0% | -17.2% | +11.1% | +2.9% | +116.5% | -57.7% | -4.4% | +12.5% |
| YoY Change | — | — | — | — | +25.2% | +25.2% | +25.2% | +25.2% | -17.2% | -8.0% | -5.3% | +105.0% | +4.8% | -9.9% | -1.5% |
Range$623.25M – $1.60B
CAGR+4.5%
Avg YoY Growth+15.3%
Median YoY Growth+4.8%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's medtech — research and development expense?
- Johnson & Johnson (JNJ) reported medtech — research and development expense of $728.00M in Q3 2025.
- How has Johnson & Johnson's medtech — research and development expense changed year-over-year?
- Johnson & Johnson's medtech — research and development expense decreased by 1.5% year-over-year, from $739.00M to $728.00M.
- What is the long-term trend for Johnson & Johnson's medtech — research and development expense?
- Over 2 years (2022 to 2024), Johnson & Johnson's medtech — research and development expense has grown at a 21.9% compound annual growth rate (CAGR), from $2.49B to $3.70B.
- What does medtech — research and development expense mean?
- The amount spent on developing new medical devices and improving existing ones.